Lifeloc Technologies (LCTC) lifts Q2 2026 revenue to $2.445M and narrows loss
Rhea-AI Filing Summary
Lifeloc Technologies, Inc. reported stronger results for the quarter ended June 30, 2026. Net revenue was $2.445 million, up from $2.219 million a year earlier, and the net loss narrowed to $(134) thousand, or $(0.05) per diluted share, from $(394) thousand, or $(0.14) per share.
Gross margin improved to 45% from 42%, helped by price increases and favorable product mix, while research and development spending remained elevated at $560 thousand, largely for the SpinDetect™ analyzer. The company advanced SpinDetect development and is targeting a limited commercial launch of its oral-fluid drug analyzer in Q1 2027. During the quarter, Lifeloc also secured a $500,000 related-party term loan at 10.5% interest, secured by all company assets.
Positive
- Revenue growth and narrowed loss: Q2 2026 net revenue rose to $2.445 million from $2.219 million, while the quarterly net loss improved to $(134) thousand from $(394) thousand, indicating materially better operating performance versus the prior-year quarter.
- Margin expansion: Total gross margin increased to 45% in Q2 2026 from 42% a year earlier, with price increases and favorable product mix contributing to improved profitability despite continued investment in R&D.
Negative
- None.
Filing Explained
As of June 30, 2026, Lifeloc reported $908,208 cash, a $460,922 related-party term-loan liability, and beta testing still planned.
The August 14 8-K furnishes Lifeloc’s results for the quarter ended
This places the analyzer at a planned beta-testing stage rather than a disclosed commercial launch, so the rollout remains tied to the stated testing and launch milestones.
At
Cash and equivalents were
Sources and calculations
- Lifeloc Technologies Form 8-K, including Exhibit 99.1 (2026-08-14)
- Lifeloc Technologies latest quarterly fundamentals (2026Q2)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $908,208 / ($133,212 / 90) = [object Object]
8-K Event Classification
Key Figures
Key Terms
gross margin financial
deferred revenue financial
beta-testing agreement technical
subordinated debentures financial
Real-time Alcohol Detection And Recognition technical
Earnings Snapshot
FAQ
How did Lifeloc Technologies (LCTC) perform financially in Q2 2026?
What were Lifeloc Technologies (LCTC) year-to-date results for the first half of 2026?
How did Lifeloc Technologies’ (LCTC) gross margins change in 2026?
What progress did Lifeloc Technologies (LCTC) report on the SpinDetect™ platform?
What new financing did Lifeloc Technologies (LCTC) secure in Q2 2026?
What is Lifeloc Technologies’ (LCTC) cash position as of June 30, 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): August 14, 2026 (
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On August 13, 2026, Lifeloc Technologies, Inc. (the “Company”) issued a press release announcing its operating results for the period ended June 30, 2026. This press release was made available on the Company’s website as of August 13, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
The information in this Form 8-K, including the exhibit attached hereto, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended, unless expressly set forth by specific reference in such filing that such information is incorporated by reference therein.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Press Release, dated August 13, 2026, issued by the Company |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 14, 2026 | LIFELOC TECHNOLOGIES, INC. | |
| By: | /s/ Vern D. Kornelsen | |
| Chief Financial Officer and Secretary | ||
Exhibit 99.1
Lifeloc Reports Second Quarter 2026 Results
WHEAT RIDGE, Colo., August 13, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2026.
Second Quarter Financial Highlights
Lifeloc posted quarterly net revenue of $2.445 million in the second quarter of 2026, resulting in a quarterly net loss of $(134) thousand, or $(0.05) per diluted share. These results compare to net revenue of $2.219 million and quarterly net loss of $(394) thousand, or $(0.14) per diluted share in the second quarter of 2025. Revenue for the quarter grew 10% versus the second quarter last year. Six-month net revenues of $4.739 million and a net loss of $(287) thousand, or $(0.10) per diluted share, compared to net revenue of $4.496 million and a net loss of $(686) thousand, or $(0.25) per diluted share, for the same period in 2025. Total gross margin in the second quarter rose to 45% versus 42% for the same quarter last year. For the first six months of 2026, gross margin was 44% versus 41% for the same period last year, with price increases and a favorable product mix contributing to the higher margins. The research and development investment for the quarter remained high at $560 thousand, primarily for SpinDetect™ analyzer development, resulting in the current period loss.
Alcohol Detection Products
We believe our core alcohol detection product line-up is strong. The L-series LX9 and LT7 units have features and performance that drive market penetration by meeting previously unaddressable market needs, such as smart phone pairing, wider temperature use ranges and fast customization that incorporates local languages. We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as the latest AS 3547:2019 standards for Breath Alcohol Detectors from SAI Global (formerly Standards Australia International). Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and has contributed to market share gains across the board, especially for our workplace Phoenix® 6.0 BT and EV 30 devices.
SpinDetect™ Analyzer Platform
We believe our most significant long-term opportunity lies at the intersection of the global need for rapid, quantitative drug detection and our proven expertise in portable testing instrumentation. Our SpinDetect™ Centrifugal Drug Analyzer — sometimes referred to as "Lab on a Disk" — is designed to address this need, enabling rapid, on-site, quantitative drug testing for use at roadside, in emergency rooms, forensic labs, and workplace testing sites. We have demonstrated the platform's ability to effectively detect delta-9-THC, cocaine, fentanyl, amphetamine/methamphetamine, morphine, MDMA, and benzodiazepines from oral fluid. We have validated our test results against liquid chromatography-mass spectrometry (LC-MS) — the definitive laboratory standard — using real-world human saliva samples, confirming a limit of detection of approximately 10 ng/ml.
We have completed the design of the SpinDetect™ microfluidic disk, with all analytical chemistry now occurring on the disk after sample introduction. Disk design represented the primary technical challenge throughout the project, requiring specialized outside expertise and multiple design iterations. Disks have been molded and assays loaded for evaluation, with final component and process optimization ongoing. Reader hardware, firmware, drug assays, and reagent handling have been developed in parallel and are substantially complete. We will be initiating beta testing of the oral-fluid analyzer, focused on delta-9-THC detection using a prototype reader, under a signed beta-testing agreement, and are now targeting a limited commercial launch in Q1 of 2027.
“It is great to see assays performed with all the chemistry occurring on the disk. With our second dispensing robot scheduled for delivery later this month, we are moving closer to production,” commented Dr. Wayne Willkomm, President and CEO. “Oral fluid drug screening will only be the first launching application of this technology platform. We expect subsequent releases to expand to additional drug panels and to samples collected from blood and breath, as well as to other applications, including select non-drug applications such as food pathogen detection.”
Financing Update
During the quarter, Lifeloc closed on $500,000 of financing, securing a loan from our Chairman of the Board, who also serves as our Chief Financial Officer. This loan is detailed in our 8-K filing of May 8, 2026, and the key terms are 10.5% interest, adjustable upward based on the prime rate, interest only payments in 2026, followed by monthly payments that will result in the loan being fully paid in 5 years, and no prepayment penalty. The loan is secured by all of our assets. After exploring multiple financing options, the Company determined these terms were more favorable than alternatives available from commercial sources.
About Lifeloc Technologies
Lifeloc Technologies, Inc. (OTCID: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, market liquidity for our shares, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.
Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc.
SpinDetect™ is a trademark of Lifeloc Technologies, Inc.
Amy
Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500
LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets (Unaudited)
| ASSETS | ||||||||
| CURRENT ASSETS: | June 30, 2026 | December 31, 2025 | ||||||
| Cash and cash equivalents | $ | 908,208 | $ | 746,001 | ||||
| Accounts receivable, net | 826,715 | 772,380 | ||||||
| Inventories, net | 2,839,516 | 2,633,614 | ||||||
| Federal and state income taxes receivable | 55,981 | 55,981 | ||||||
| Prepaid expenses and other | 146,901 | 60,825 | ||||||
| Total current assets | 4,777,321 | 4,268,801 | ||||||
| PROPERTY, PLANT AND EQUIPMENT: | ||||||||
| Land | 317,932 | 317,932 | ||||||
| Building | 1,928,795 | 1,928,795 | ||||||
| Real-time Alcohol Detection And Recognition equipment and software | 569,448 | 569,448 | ||||||
| Production equipment, software and space modifications | 1,366,539 | 1,366,539 | ||||||
| Office equipment, software and space modifications | 197,686 | 197,686 | ||||||
| Sales and marketing equipment and space modifications | 230,543 | 225,173 | ||||||
| Research and development equipment, software and space modifications | 1,247,201 | 1,213,195 | ||||||
| Research and development equipment, software and space modifications not in service | — | 19,595 | ||||||
| Less accumulated depreciation | (3,670,607 | ) | (3,538,455 | ) | ||||
| Total property and equipment, net | 2,187,537 | 2,299,908 | ||||||
| OTHER ASSETS: | ||||||||
| Patents, net | 67,229 | 71,039 | ||||||
| Deposits and other | 46,820 | 46,820 | ||||||
| Total other assets | 114,049 | 117,859 | ||||||
| Total assets | $ | 7,078,907 | $ | 6,686,568 | ||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | $ | 501,118 | $ | 301,627 | ||||
| Term loans payable, current portion | 94,774 | 54,850 | ||||||
| Subordinated debentures payable, current portion | 35,697 | 33,371 | ||||||
| Customer deposits | 20,336 | 25,694 | ||||||
| Accrued expenses | 350,141 | 321,112 | ||||||
| Deferred revenue, current portion | 50,464 | 53,716 | ||||||
| Product warranty reserve | 46,500 | 46,500 | ||||||
| Total current liabilities | 1,099,030 | 836,870 | ||||||
| TERM LOAN PAYABLE, net of current portion and debt issuance costs | 1,030,364 | 1,058,426 | ||||||
| TERM LOAN PAYABLE (Related Party), net of current portion and debt issuance costs | 460,922 | — | ||||||
| SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs | 662,901 | 681,343 | ||||||
| DEFERRED REVENUE, net of current portion | 8,955 | 6,151 | ||||||
| Total liabilities | 3,262,172 | 2,582,790 | ||||||
| COMMITMENTS AND CONTINGENCIES (Note 6) | ||||||||
| STOCKHOLDERS’ EQUITY: | ||||||||
| Common stock, no par value; 50,000,000 shares authorized, 2,752,616 shares outstanding | 5,934,314 | 5,934,314 | ||||||
| Accumulated deficit | (2,117,579 | ) | (1,830,536 | ) | ||||
| Total stockholders’ equity | 3,816,735 | 4,103,778 | ||||||
| Total liabilities and stockholders’ equity | $ | 7,078,907 | $ | 6,686,568 | ||||
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Profit (Loss) (Unaudited)
| Three Months Ended June 30, | ||||||||
| REVENUES: | 2026 | 2025 | ||||||
| Product sales | $ | 2,434,697 | $ | 2,191,260 | ||||
| Royalties | 10,260 | 19,800 | ||||||
| Rental income | — | 8,316 | ||||||
| Total | 2,444,957 | 2,219,376 | ||||||
| COST OF SALES | 1,352,431 | 1,294,777 | ||||||
| GROSS PROFIT | 1,092,526 | 924,599 | ||||||
| OPERATING EXPENSES: | ||||||||
| Research, development, and sustaining engineering | 560,281 | 623,262 | ||||||
| Sales and marketing | 320,968 | 339,528 | ||||||
| General and administrative | 314,853 | 340,074 | ||||||
| Total | 1,196,102 | 1,302,864 | ||||||
| OPERATING (LOSS) | (103,576 | ) | (378,265 | ) | ||||
| OTHER INCOME (EXPENSE): | ||||||||
| Interest income | 8,856 | 10,931 | ||||||
| Interest expense | (39,610 | ) | (26,305 | ) | ||||
| Total | (30,754 | ) | (15,374 | ) | ||||
| NET (LOSS) BEFORE PROVISION FOR TAXES | (134,330 | ) | (393,639 | ) | ||||
| BENEFIT FROM FEDERAL AND STATE INCOME TAXES | — | — | ||||||
| NET (LOSS) | $ | (134,330 | ) | $ | (393,639 | ) | ||
| NET (LOSS) PER SHARE, BASIC | $ | (0.05 | ) | $ | (0.14 | ) | ||
| NET (LOSS) PER SHARE, DILUTED | $ | (0.05 | ) | $ | (0.14 | ) | ||
| WEIGHTED AVERAGE SHARES, BASIC | 2,752,616 | 2,752,616 | ||||||
| WEIGHTED AVERAGE SHARES, DILUTED | 2,752,616 | 2,752,616 | ||||||
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Profit (Loss) (Unaudited)
| Six Months Ended June 30, | ||||||||
| REVENUES: | 2026 | 2025 | ||||||
| Product sales | $ | 4,724,456 | $ | 4,454,307 | ||||
| Royalties | 14,313 | 25,471 | ||||||
| Rental income | — | 16,632 | ||||||
| Total | 4,738,769 | 4,496,410 | ||||||
| COST OF SALES | 2,659,169 | 2,663,245 | ||||||
| GROSS PROFIT | 2,079,600 | 1,833,165 | ||||||
| OPERATING EXPENSES: | ||||||||
| Research, development, and sustaining engineering | 974,726 | 1,092,942 | ||||||
| Sales and marketing | 634,197 | 674,084 | ||||||
| General and administrative | 702,255 | 724,952 | ||||||
| Total | 2,311,178 | 2,491,978 | ||||||
| OPERATING (LOSS) | (231,578 | ) | (658,813 | ) | ||||
| OTHER INCOME (EXPENSE): | ||||||||
| Interest income | 15,387 | 23,288 | ||||||
| Interest expense | (70,852 | ) | (50,800 | ) | ||||
| Total | (55,465 | ) | (27,512 | ) | ||||
| NET (LOSS) BEFORE PROVISION FOR TAXES | (287,043 | ) | (686,325 | ) | ||||
| BENEFIT FROM FEDERAL AND STATE INCOME TAXES | — | — | ||||||
| NET (LOSS) | $ | (287,043 | ) | $ | (686,325 | ) | ||
| NET (LOSS) PER SHARE, BASIC | $ | (0.10 | ) | $ | (0.25 | ) | ||
| NET (LOSS) PER SHARE, DILUTED | $ | (0.10 | ) | $ | (0.25 | ) | ||
| WEIGHTED AVERAGE SHARES, BASIC | 2,752,616 | 2,723,768 | ||||||
| WEIGHTED AVERAGE SHARES, DILUTED | 2,752,616 | 2,723,768 | ||||||
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Changes in Stockholders’ Equity (Unaudited)
For the Three and Six Months Ended June 30, 2026 and 2025
| 2026 | ||||||||||||||||
| Common Stock Shares | Common Stock Amount | Accumulated Deficit | Total | |||||||||||||
| Beginning balance, December 31, 2025 | 2,752,616 | $ | 5,934,314 | $ | (1,830,536 | ) | $ | 4,103,778 | ||||||||
| Net (loss) | — | — | (152,713 | ) | (152,713 | ) | ||||||||||
| Ending balance, March 31, 2026 | 2,752,616 | 5,934,314 | (1,983,249 | ) | 3,951,065 | |||||||||||
| Net (loss) | — | — | (134,330 | ) | (134,330 | ) | ||||||||||
| Ending balance, June 30, 2026 | 2,752,616 | $ | 5,934,314 | $ | (2,117,579 | ) | $ | 3,816,735 | ||||||||
| 2025 | ||||||||||||||||
| Common Stock Shares | Common Stock Amount | Accumulated Deficit | Total | |||||||||||||
| Beginning balance, December 31, 2024 | 2,664,116 | $ | 5,586,014 | $ | 639,863 | $ | 6,225,877 | |||||||||
| Issuance of shares from option exercise | 88,500 | 336,300 | — | 336,300 | ||||||||||||
| Warrants issued with subordinated debenture | — | 12,000 | — | 12,000 | ||||||||||||
| Net (loss) | — | — | (292,686 | ) | (292,686 | ) | ||||||||||
| Ending balance, March 31, 2025 | 2,752,616 | 5,934,314 | 347,177 | 6,281,491 | ||||||||||||
| Net (loss) | — | — | (393,639 | ) | (393,639 | ) | ||||||||||
| Ending balance, June 30, 2025 | 2,752,616 | $ | 5,934,314 | $ | (46,462 | ) | $ | 5,887,852 | ||||||||
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Cash Flows (Unaudited)
| Six months Ended June 30, | ||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | 2026 | 2025 | ||||||
| Net (loss) | $ | (287,043 | ) | $ | (686,325 | ) | ||
| Adjustments to reconcile net (loss) to net cash (used in) operating activities- | ||||||||
| Depreciation and amortization | 135,962 | 216,419 | ||||||
| Amortization of debt issuance costs | 12,103 | 5,886 | ||||||
| Changes in operating assets and liabilities- | ||||||||
| Accounts receivable | (54,335 | ) | (33,189 | ) | ||||
| Inventories | (205,902 | ) | 7,645 | |||||
| Federal and state income taxes receivable | — | 25,029 | ||||||
| Prepaid expenses and other | (86,076 | ) | (120,034 | ) | ||||
| Deposits and other | — | — | ||||||
| Accounts payable | 199,491 | 141,419 | ||||||
| Customer deposits | (5,358 | ) | (6,186 | ) | ||||
| Accrued expenses | 29,029 | 55,416 | ||||||
| Deferred revenue | (448 | ) | 4,344 | |||||
| Net cash (used in) operating activities | (262,577 | ) | (389,576 | ) | ||||
| CASH FLOWS (USED IN) INVESTING ACTIVITIES: | ||||||||
| Purchases of sales and marketing equipment | (5,370 | ) | (5,462 | ) | ||||
| Purchases of research and development equipment, software and space modifications | (14,411 | ) | (17,348 | ) | ||||
| Purchases of research and development equipment, software and space modifications not in service | — | (219,441 | ) | |||||
| Net cash (used in) investing activities | (19,781 | ) | (242,251 | ) | ||||
| CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES: | ||||||||
| Principal payments made on term loan | (28,290 | ) | (27,469 | ) | ||||
| Proceeds from issuance of subordinated debenture | — | 75,000 | ||||||
| Proceeds (related party) from issuance of term loan | 500,000 | — | ||||||
| Principal payments made on subordinated debentures | (27,145 | ) | — | |||||
| Proceeds from issuance of shares from option exercise | — | 336,300 | ||||||
| Net cash provided from (used in) financing activities | 444,565 | 383,831 | ||||||
| NET INCREASE (DECREASE) IN CASH | 162,207 | (247,996 | ) | |||||
| CASH, BEGINNING OF PERIOD | 746,001 | 1,243,746 | ||||||
| CASH, END OF PERIOD | $ | 908,208 | $ | 995,750 | ||||
| SUPPLEMENTAL INFORMATION: | ||||||||
| Cash paid for interest | $ | 59,264 | $ | 44,914 | ||||
| Cash paid for income tax | $ | — | $ | 150 | ||||
| Income tax refund received | $ | — | $ | 25,179 | ||||
| Non-cash financing and investing activities: warrants issued with subordinated debenture | $ | — | $ | 12,000 | ||||